PASSAGE BIO, INC. Investment Income, Net
PASSAGE BIO, INC. (PASG) reported Investment Income, Net of $2.27 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-06.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2023-03-06
- PASSAGE BIO, INC. investment income, net for the quarter ending 2022-12-31 was $1.17M, a 19450.00% increase year-over-year.
- PASSAGE BIO, INC. investment income, net for the quarter ending 2022-09-30 was $825.00K, a 343.55% increase year-over-year.
- PASSAGE BIO, INC. investment income, net for the quarter ending 2022-06-30 was $270.00K, a 172.73% increase year-over-year.
- PASSAGE BIO, INC. investment income, net for the quarter ending 2022-03-31 was $1.00K.
- PASSAGE BIO, INC. investment income, net for fiscal 2022 was $2.27M, a 561.52% increase from fiscal 2021.
- PASSAGE BIO, INC. investment income, net for fiscal 2021 was $343.00K.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2022-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $2.00M derived: sum of 2 quarters · filed 2023-03-06 | $2.27M derived: sum of 3 quarters · filed 2023-03-06 | $2.27M 10-K · filed 2023-03-06 |
| 2022-09-30 | $825.00K 10-Q · filed 2022-11-10 | $1.09M derived: sum of 2 quarters · filed 2022-11-10 | $1.10M 10-Q · filed 2022-11-10 | $1.10M derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | $270.00K 10-Q · filed 2022-08-04 | $271.00K 10-Q · filed 2022-08-04 | $277.00K derived: sum of 3 quarters · filed 2023-03-06 | $463.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | $1.00K derived: 10-K 12 month − 3 quarters · filed 2023-03-06 | $7.00K derived: sum of 2 quarters · filed 2023-03-06 | $193.00K derived: sum of 3 quarters · filed 2023-03-06 | $292.00K derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $192.00K derived: sum of 2 quarters · filed 2023-03-06 | $291.00K derived: sum of 3 quarters · filed 2023-03-06 | $343.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $186.00K 10-Q · filed 2022-11-10 | $285.00K derived: sum of 2 quarters · filed 2022-11-10 | $337.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $99.00K 10-Q · filed 2022-08-04 | $151.00K 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |